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of Neuroinflammation
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Elisa Mitiko Kawamoto and Cristoforo Scavone*
Department of Pharmacology, Institute of Biomedical Science, University of São Paulo, São Paulo, Brazil
Cardiotonic steroids (CTS) are a class of specific ligands of the Na+, K+- ATPase (NKA). 
NKA is a P-type ATPase that is ubiquitously expressed and although well known to 
be responsible for the maintenance of the cell electrochemical gradient through active 
transport, NKA can also act as a signal transducer in the presence of CTS. Inflammation, 
in addition to importantly driving organism defense and survival mechanisms, can also 
modulate NKA activity and memory formation, as well as being relevant to many chronic 
illnesses, neurodegenerative diseases, and mood disorders. The aim of the current 
review is to highlight the recent advances as to the role of CTS and NKA in inflammatory 
process, with a particular focus in the central nervous system.
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iNTRODUCTiON
Inflammation is an important contributor to the protection of the organism against injuries and in 
the maintenance of homeostasis (1), as well as being relevant in the central nervous system (CNS) to 
a number of key processes, including memory formation (2). However, in chronic and uncontrolled 
pathological conditions, such as diabetes (3), Alzheimer’s disease (4), and Parkinson’s disease (5), 
inflammatory processes can be detrimental. Inflammatory processes can modulate the activity of 
many different proteins, including Na+,K+-ATPase (NKA) (6), which is a conserved membrane pro-
tein that maintains the electrochemical gradient of the cell membrane using ATP as its energy source. 
Cardiotonic steroids (CTS) are natural ligands of NKA that can, in a dose-dependent manner, inhibit 
NKA pump activity (7) or trigger the activation of signaling pathways, such as Ras–Raf–MAPK 
and inositol trisphosphate receptor (InsP3R) activity, which can evoke calcium oscillations, in turn 
leading to the activation of the inflammation-associated transcription factor nuclear factor-kappa 
B (NF-κB) (8).
Numerous studies have shown CTS to modulate the function of many immune cells, both in vitro 
and in vivo, with effects via the inhibition of NF-κB and MAPK, thereby controlling some key cellular 
processes, such as proliferation and differentiation, as well as cytokine production (9–14).
This article reviews the literature addressing CTS effects in immune modulation, with a particular 
emphasis on effects in the CNS. This is of some importance as a growing body of data indicates a 
significant role for central inflammatory processes in the etiology and course of many neurodegen-
erative diseases and mood disorders.
Na+,K+-ATPase: A BRieF DeSCRiPTiON
For many years, NKA has aroused the interest of many groups in studying not only its pumping 
function, structure, and biochemistry but also, more recently, its role in signal transduction (15–17). 
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NKA is well known to be responsible for the maintenance of ionic 
homeostasis where the hydrolysis of one molecule of ATP allows 
the establishment of an electrochemical gradient through the 
cellular efflux of three Na+ ions and an influx of two K+ ions. 
NKA is also important to the provision of cellular energy, through 
the cotransport of other substances, over the plasma membrane, 
given that many co- or counter-transporters use the Na+ and K+ 
ionic gradients (18). A further crucial role for the NKA is the 
re-establishment of the ionic gradient following neuronal action 
potential firing. This is due to the natural Na+ and K+ diffusion 
potential across the cell membrane, which establishes a steady 
state that is vital for all excitable tissues, and which needs to be 
repolarized after neuronal depolarization (15, 18).
NKA consists of two protomers, each is composed of α- and 
β-subunits associated with a third protein, the γ-subunit or 
FXYD2 (18). Four different isoforms of the NKA α-subunit have 
been identified (α1–4), three β isoforms (β1–3), and seven differ-
ent FXYD accessory proteins (19). Interestingly, the distribution 
of the different isoforms varies according to cell type, tissue, stage 
of development, and species (19–21). The isoforms α1, α2, α3, 
and α4 have different expression profiles, with the α1 subunit 
being ubiquitously expressed and uniformly distributed, α2 being 
predominant in some specific cell types, including astrocytes and 
cardiac myocytes, α3 being more highly expressed in neurons 
and the ovaries, while α4 can be found only in spermatozoa (15, 
19, 22, 23). The NKA β-subunit seems to be a specific chaperone 
that is essential for both the traffic and correct plasma insertion 
site of newly synthesized α-subunits (24). Furthermore, the 
β-subunit can even influence pump activity, given its modulation 
of K+ affinity for the pump binding sites (25, 26). Interestingly, β1 
and β2 isoforms can both be found in the brain, with astrocytes 
expressing α1 and α2 in combination with β2, while neurons 
express α1 and α3 in combination with β1 or β2 (15, 27).
iMPORTANCe OF NKA SUBUNiTS iN 
iNFLAMMATiON: A GeNeRAL APPROACH
Over the last decade, many studies have suggested an interesting 
relationship between inflammatory process and the different 
NKA subunits, the main points of which will be summarized here.
It is well established that mitogenic activation of human 
peripheral blood lymphocytes by phytohemagglutinin (PHA) is 
accompanied by an enhancement of NKA activity, followed by an 
increase in K+ and Na+ transport (28, 29). This is dependent on 
new protein transcription (30, 31), and follows α1 and β1 mRNA 
up-regulation (32). In 2002, Chiampanichayakul et al. showed for 
the first time that an antibody anti-NKA β3 subunit was able to 
down-regulate the proliferation of both T- and B-lymphocytes, 
as well as the production of interleukin (IL)-2, IL-4, IL-10, and 
interferon-gamma (IFN-γ), in vitro (33).
In a model of systemic inflammation, male Sprague-Dawley 
rats that received an injection of Complete Freund’s adjuvant, 
which includes inactivated Mycobacterium tuberculosis, presented 
both α1- and α3-NKA isoform up-regulations, especially in 
primary afferent neurons, after 23 and 24 h (34). Furthermore, a 
recent study has brought some new insight as to how NKA may 
be involved in inflammatory processes in the somatosensory 
system (35). This study suggested that the FXYD2 subunit interac-
tion with α1-subunit in murine nociceptive neurons negatively 
regulated pump activity, leading to membrane potential depo-
larization of these neurons, which can facilitate excitatory affer-
ent neurotransmission, thereby facilitating allodynia. When the 
group used FXYD2-deficient mice, allodynia was more quickly 
abolished (35).
In general, it seems that the differences in the NKA isoform 
functions and distribution contribute somehow to the complexity 
of the inflammatory responses.
In 4-month-old rat hippocampus, the systemic injection of 
lipopolysaccharide (LPS) decreased both total NKA activity, and 
α2 and α3 isoforms, although in adult rats there was no signifi-
cant difference (36). In accordance with these findings, in vitro 
experiments showed that inflammation induced by LPS-treated 
primary astrocytes co-cultured with newborn cortex endothelial 
cells also involves NKA downregulation (37). An LPS-dependent 
decrease in total NKA activity in young rats can be rescued by 
intermittent fasting (IF), as well as in older rats to a lesser degree 
(36), suggesting an age-associated susceptibility of NKA activity 
modulation by inflammatory process.
However, in the rat cerebellum, there is an age-related decline 
of NKA activity, arising from a decrease in the cyclic GMP–PKG 
pathway in cerebellum. There is also an effect of glutamatergic 
activity in the modulation of alpha 2,3-NKA due to impairments 
in PKG signaling. A failure in the correction of ionic disturbances 
mechanism present in aging processes could also increase the 
probability of occurrence of degenerative disorders (38). As such, 
NKA activity can be modulated by different stimuli, with conse-
quences for the neuro-inflammatory processes that are present in 
all neurodegenerative diseases (39) (Figure 1).
NKA AND NeUROiNFLAMMATiON
In the CNS, inflammatory processes utilize a wide array of 
immunological cells, including the resident immunological cells, 
microglia, and astrocytes (40). However, in a pathological situa-
tion, monocyte-derived macrophages, present in the perivascular 
space, are able to cross the blood–brain barrier (BBB), with 
lymphocytes also being able to transverse the epithelial blood–
cerebrospinal fluid barrier (BCSFB) surrounding the choroid 
plexus (41–43).
When exposed to cytokines, innate immune modulators, 
hypoxia, or other damaging stimuli, astrocytes are able to release 
cytokines and other immune signaling molecules (40, 44), fol-
lowed by changes in Ca2+ signaling system and Na+ transports 
during inflammation (37). Little can be stated generally about 
the microglial response, due to inflammation heterogeneity and 
complexity in different pathological contexts (45).
It is important to note that NKA plays a significant role in 
central inflammation, which is apparent in diabetic rats, where 
inflammation-associated increases in tumor necrosis factor 
(TNF)-α and IL-1β, as well as decreased NKA activity, result in 
memory impairment (46). Similarly, decreased NKA activity is 
evident in a model of traumatic brain injury (TBI) (47), which is 
FiGURe 1 | Neurodegeneration and NKA. Astrocytes are important to regulate the release of glutamate and its provision to neurons. NKA has an important role 
in the control of the glutamate transporter-1 (GLT-1) in astrocytes, because the concentration of Na+ modulates the uptake of glutamate (55). The adenosine A2A 
receptor decreases NKA activity, leading to increased intracellular Na+ concentration, which impairs glutamate uptake, resulting in more glutamate availability in the 
synaptic cleft (55). Such excess of glutamate overactivates the NMDA receptor, leading to increase intracellular Na+ and Ca2+, in turn driving excitotoxicity (55). The 
decrease of NKA is mostly deleterious and amylospheroids, which are composed of β-amyloid oligomers and α-synuclein, interact with α3-NKA, thereby impairing 
its activity. Such data indicate NKA to have an important role in neurodegeneration and neurodegenerative diseases (52, 53). Our group showed that aging is also 
an important factor that decreases NKA activity (36, 38).
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prevented by exercise pre-conditioning, indicating that modulating 
NKA can determine the brain’s subsequent response to damage (6).
Differences between brain region responses during systemic 
inflammation have been found in an animal model of sepsis, with 
NKA inhibition being faster in the cortex versus the hippocam-
pus (48). This effect is not due to differences in NKA mRNA levels 
or in NKA isoforms, but could be due to a post-translational 
modification or to an altered oxidative stress response. Only in 
the cortex does an increase in NKA activity follow antioxidant 
administration, suggesting that variations in oxidative status 
may play a more important role in the regulation of cortical NKA 
and thereby have a differential effect on the cortex inflammatory 
response versus that in the hippocampus (48). The hippocampus 
seems more vulnerable to inflammation and, at least partly via 
differential NKA antioxidant effects, is more vulnerable in neuro-
degenerative diseases, including Alzheimer’s disease (49).
In postmortem brains of Alzheimer’s disease patients, NKA 
activity is diminished compared to that of age-matched normal 
brains (50). Such results were reproduced in an in vitro model of 
hippocampal neurons treated with β-amyloid (51), as well as in 
an in vitro model of frontal cortex neurons, where the addition 
of antioxidants, such as genistein, afforded a protective effect by 
increasing NKA activity (50). The mechanism underlying such 
decreased NKA activity was recently proposed. The amylo-
spheroids, amyloid β-protein (Aβ) oligomers typically found in 
postmortem brains of Alzheimer’s disease patients, can interact 
with α3-NKA impairing its activity, in turn leading to the acti-
vation of voltage-dependent calcium channels, mitochondrial 
abnormalities, and neurodegeneration (52) (Figure 1).
In addition, an increased sodium concentration in frontal and 
parietal cortex, as well as an increased potassium concentration 
in the cerebellar tissue of Alzheimer’s disease patients has also 
been shown. The same pattern appears in the cerebrospinal fluid 
(CSF) and was also replicated in  vitro when astrocytes were 
treated with β-amyloid protein. In fact, Alzheimer’s disease is also 
related to impaired glutamate clearance, which contributes to an 
ionic imbalance (53).
During inflammation, an increase in N-methyl d-aspartate 
(NMDA) receptor phosphorylation is observed, with increased 
IL-1β release from astrocytes also evident (54). When a co-culture 
model of astrocytes pre-activated by an inflammatory stimulus was 
treated with Ifenprodil, Lundborg and colleagues observed that this 
drug could be a potent anti-inflammatory in astrocytes, following 
its restoration of Ca2+ levels and increased NKA expression (54).
In astrocytes, there is a crosstalk between α2-NKA isoform 
and GLT-I, an astrocytic glutamate transporter, that seems to 
be regulated by the Na+ pump (55) (Figure  1). Furthermore, 
adenosine A2A receptors (A2AR), present in astrocytes, have 
an important role in plasticity and neurodegeneration (55). The 
activation of these receptors decreases NKA activity, which, as a 
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result, inhibits glutamate uptake. In a model of A2AR knockout 
animals, increased astrocytic glutamate uptake occurred, coupled 
to increased expression of α2-NKA in the cortex and striatum. 
This suggests a role for NKA in neurodegeneration (55), includ-
ing Parkinson’s disease, given that in 2004, it was discovered 
that α3-NKA mutations are involved in rapid-onset dystonia 
parkinsonism that reveals that NKA could have an important 
role in Parkinson’s disease (56). Of note, extracellular α-synuclein 
can interact with α3-NKA to form clusters in the membrane of 
neurons that reduce the extrusion of Na+ and which may be a 
relevant neuropathological change in Parkinson’s disease (57). 
In addition, there is also evidence that α1-NKA overexpression 
drives axon initial segment abnormalities and that by reducing 
its expression, these and other phenotypes could be corrected in 
an Angelman syndrome murine model (58). The lack of NKA 
is involved in neurodegeneration given that α-NKA deletion in 
Drosophila photoreceptors lead to the loss of visual function, as 
well as an increase in neurodegeneration (59).
CARDiOTONiC STeROiDS, THe SPeCiFiC 
LiGANDS OF NKA
Cardiotonic steroids are a class of compounds that have been 
used to treat congestive heart failure since the eighteenth century 
(60). These compounds bind specifically to NKA, inhibiting its 
activity in a dose-dependent manner. Furthermore, they can also 
activate wider cellular signaling pathways, mediating changes in 
intracellular Ca2+ homeostasis, control of cellular growth, and 
gene expression (19, 61–64).
Cardiotonic steroids can be divided into cardenolides and 
bufadienolides, according to their origins (7) and molecular 
structure (19, 65, 66), being subsequently classified as endog-
enous hormones in the 1990s. Two cardenolides, digoxin (67) 
and ouabain (68), and several bufadienolides (69–71) have been 
identified in human tissues. They are proposed to be produced in 
the hypothalamus and adrenal gland (19, 64, 72), although there 
is some controversy regarding this, as some work has failed to 
show their presence in human plasma (73).
Numerous studies have shown CTS, as natural ligands of 
NKA, to have modulatory effects on immune cells functioning 
in vitro and in vivo (9–11, 13, 14).
ANTi-iNFLAMMATORY PROPeRTieS 
OF CTS
In 1997, Matsumori et al. demonstrated that ouabain reduced the 
production of the pro-inflammatory cytokines, IL-6 and TNF-α, 
in LPS-stimulated human peripheral blood mononuclear cells, as 
similarly observed in vivo, in LPS-treated mice (12). Following 
this work, other studies have demonstrated anti-inflammatory 
and analgesic effects of CTS in mice. In the classical paw edema 
model, pretreatment with ouabain reduced carrageenan-, 
zymosan-, 48/80-, and PGE2-induced edema and vascular 
permeability (14, 74), with bufalin leading to a reduction in 
carrageenan-induced paw edema, due to the inhibition of NF-κB 
activation and reduced pro-inflammatory protein expression, 
including inducible nitric oxide synthase (iNOS), cyclooxyge-
nase-2, TNF-α, IL-1β, and IL-6 (13). Furthermore, bufalin has 
an antinociceptive effect, due, at least in part, to its reduction 
of TNF-α and IL-1β release (13). Moreover, bufalin inhibits 
inflammation and migration of TNF-α-induced fibroblast-like 
synoviocytes, as well as reducing IL-1β, IL-6, IL-8 expression and 
decreasing the secretion of matrix metalloproteinase-9 (MMP-9), 
driven by its suppression of NF-κB activation. These results sug-
gest a potential modulatory effect of bufalin in diseases, such as 
rheumatoid arthritis (75).
Similar to bufalin, ouabain has the ability to reduce pro-
inflammatory cytokine production, such as IL-1β and TNF-α, 
likewise inhibiting NF-κB and p38 MAPK signaling pathways (11, 
14) as demonstrated in a study showing that ouabain decreases 
intraperitoneal polymorphonuclear cell concentrations induced 
by several stimuli, as well as inhibiting leukocyte migration 
in vitro (14, 74, 76). A similar anti-inflammatory effect was also 
seen with oleandrin and digitoxin (77, 78).
Recently, a subset of IL-17-producing cells has been linked to 
chronic inflammatory processes (79). These cells are described as 
a new population of effector T cells, known as Th17 cells (80), and 
are characterized by retinoic acid orphan receptor (ROR)-γt tran-
scription factor and by IL-17A and IL-17F production (81), but 
not T-bet or GATA-3 transcription factors (82). Several studies 
have investigated digoxin effects in Th17 cells (83–85). Treatment 
with digoxin, in a mouse and human CD4+ T cell culture, inhib-
ited naïve CD4 polarization to Th17 cells and reduced IL-17A 
protein expression. These effects were due to the inhibition of 
RORγt transcriptional activity. Furthermore, in experimental 
autoimmune encephalomyelitis, a multiple sclerosis model and 
Th17-mediated disease, treatment with digoxin, delays disease 
onset and reduces disease severity. IL-17 levels produced by 
infiltrating cells were also decreased (83).
Taken together, numerous studies have shown CTS to modu-
late the function of immune cells in vitro and in vivo. These anti-
inflammatory effects are mainly mediated through NF-κB and 
MAPK inhibition. Besides CTS effects in the periphery as indi-
cated above, some studies have also been carried out in the CNS, 
although the exact mechanisms or signaling pathways involved are 
still poorly understood. In the next section, studies are described 
that evaluate the functions of CTS in neuroinflammation.
CTS AND iMMUNe ReSPONSe iN 
THe CNS
Neuroinflammation is currently a hot topic, primarily due 
to its association with neurodegenerative diseases, such as 
Parkinson’s disease and Alzheimer’s disease, as well as its 
association with mood disorders and cancers. As such, neu-
roinflammation has become a highly significant therapeutic 
target (86).
Cardiotonic steroids can have contrasting effects on neuro-
inflammation, as determined by variations in concentration, the 
route of administration, cell type, specific brain region, and time 
course. Ouabain is one of the most studied CTS in the CNS.
FiGURe 2 | The dual role of CTS. CTS at high concentrations are deleterious, due to NKA inhibition that consequently increases intracellular Na+, which leads to 
raised intracellular Ca2+ that can be the first signal of neuronal excitotoxicity (91). There is also an increase in reactive oxygen species and in pro-inflammatory 
cytokines and a decrease in BDNF, which is a relevant growth factor in the brain (108, 109, 114). CTS also increase locomotor activity (114), particularly when the 
CTS are intracerebroventricular injected, as in the ouabain model of mania (110). CTS seem to be involved in mood disorders, such as depression and bipolar 
disorder. Low concentrations of CTS can have a protective role, including the CNS. CTS can activate anti-apoptotic protein, such as Bcl-xL, as well as increasing 
NF-κB and BDNF (88–90, 100). Our group showed that the pretreatment with ouabain can be protective against neuroinflammation caused by LPS (90). This 
protection is due to decreased IL-1β, TNF-α, and iNOS mRNA levels and in the rescue of BDNF levels, thereby reverting the changes induced by LPS and, 
consequently, decreasing astrocytic activity, as measured by dentate gyrus GFAP (90).
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Although ouabain-like compounds are supposed to be pro-
duced in the hypothalamus (47), there has been little investiga-
tion as to its central effects, including the regulation of central 
inflammatory responses and whether the CTS are able to cross 
the BBB by getting CNS entry via the fenestrated vasculature 
adjacent to the circumventricular organs (87).
Many groups have reported that low concentrations of this 
glycoside did not inhibit NKA, instead it could activate signaling 
pathways that usually result in a protective response, by increas-
ing anti-apoptotic protein expression and cell proliferation 
(88–90). When the cells are treated with higher concentrations 
of ouabain (micrometer–millimeter), NKA is inhibited and, as a 
consequence, Na+ and K+ gradients are lost leading to an influx 
of Ca2+ into the cell, which can drive neuronal excitotoxicity (91).
In a rat cerebellum cell culture treated with ouabain at 10 μM, 
an increase in NF-κB nuclear translocation was observed, thereby 
increasing the mRNA levels of Tnf-α, Il-1β, and Bdnf. In addition, 
the same study showed that ouabain-induced NF-κB activation 
was dependent on the NMDA–Src–Ras signaling trigged by the 
MAPK pathways (91). Similar results were observed in another 
study from the same group, in a model of intra-hippocampal 
injections of 10  nM ouabain concentrations in adult rats. At 
nanomolar concentration, no inhibition of the NKA activity was 
observed, and there was NF-κB activation followed by an increase 
of Tnf-α and iNos mRNA levels (92). These two studies show that 
ouabain could increase pro-inflammatory cytokines without 
NKA inhibition and that NF-κB, Src, and NMDA are involved 
in this signaling pathway. As such, ouabain could also play an 
important role in the control of NF-κB activation, which can lead 
to adaptive responses and this could have an important impact on 
hippocampal memory processes, including memory formation 
and/or consolidation (93).
In addition, a third study from the group showed that ouabain 
can also play a protective role against LPS, a LPS that causes sys-
temic immune responses and can also disrupt the BBB at higher 
concentrations. In these experiments, rats were pretreated with a 
very low concentration (1.8 μg/kg) of ouabain intraperitoneally 
before LPS. Results suggested that ouabain could decrease the 
nuclear translocation of p65, a NF-κB subunit, important in 
inflammatory responses, in the presence of LPS and also reversed 
LPS-induced decrease in cytoplasmic IκB levels. As a result, Il-1β 
and iNos gene expression were decreased in ouabain pretreat-
ment, in comparison to the LPS-only group (90) (Figure 2).
As previously described, ouabain can also increase TNF-α 
release, but when animals were treated with ouabain and then 
challenged with LPS, there was a decrease in the levels of this 
cytokine. This anti-inflammatory property of ouabain was also 
seen in the dentate gyrus, a region of the hippocampus, with 
ouabain decreasing astrocyte activity in comparison to the 
LPS-only group (90). Such data indicate that ouabain can also be 
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protective, during disturbances to CNS homeostasis, suggesting 
that ouabain alone in physiological concentrations may modulate 
cellular homeostasis, via pro-inflammatory cytokine regulation. 
It also suggests that the signaling pathway activated by ouabain 
could be an interesting target in neuroinflammation-associated 
disorders.
Interestingly, two separate studies noted that different cell 
types have specific ouabain responses. In rat cortex astrocyte 
culture, ouabain could prevent the downregulation of NKA and 
also could attenuate the raised levels of IL-1β release induced 
by LPS (94). However, in microglia, ouabain in low and high 
concentrations did not have any effect against LPS-induced 
cytokine release, although low concentration of ouabain evoked 
an increase in TNF-α release, which highlights that ouabain can 
have differential immune-modulatory effects in different cell 
types (95).
Furthermore, Kaur et  al. have also observed that digoxin 
seems to have a neuroprotective effect in an ischemia/rep-
erfusion model (96). Although, the authors did not test any 
inflammation parameter, the immune system is activated in 
this protocol with digoxin pretreatment decreasing the cerebral 
infarct size, resulting in better motor behavior and memory. 
These authors used Ca2+ channel blockers, which abolished this 
protection, suggesting efficacy via the Ca2+ signaling cascades 
(96). Another way that digoxin can be protective is by increas-
ing levels of endogenous brain hydrogen sulfide (H2S) (97). 
H2S is severely decreased in the brain of Alzheimer’s disease 
patients (98), suggesting that this could be another mechanism 
by which CTS could alleviate symptomatology in patients with 
neurodegenerative diseases, although the concentration may 
have to be very low.
Although the discussion of CTS effects on glutamatergic 
excitotoxicity is beyond the scope of this review, some data are 
worth highlighting. Ouabain, at 1 nM, seems also to be protec-
tive against kainate-induced neurotoxicity by preventing Ca2+ 
overload in the rat cortical neurons, indicating that the modula-
tion of NKA can play a key role against neuronal degeneration 
(88). The same effect seems to occur in an experimental model of 
ischemia in hippocampal slice cultures, where ouabain at 120 nM 
increases NKA activity. NKA inhibition is important to this 
ouabain-mediated protective effect, which suggest that low dose 
of ouabain and digoxin may be a plausible and novel treatment 
strategy in the management of stroke (39).
Another study showed the protective effect of oleandrin in an 
ischemia model in vitro and in vivo, suggesting that the protective 
effect of CTS in low doses is common to all types of CTS (99). It 
seems that oleandrin increased plasma brain-derived neurotrophic 
factor (BDNF) levels, this being another possible mechanism of 
protection against oxygen-glucose deprivation (100).
Neriifolin, another CTS, was used as a model of Parkinson’s 
disease, because it decreases dopaminergic neuron survival 
through NKA inhibition, which increases the concentration of 
intracellular Na+, reactive oxygen species (ROS), and p53 activa-
tion (101). Similarly, marinobufagenin (MGB) can also induce 
endothelial oxidative stress, which may be the first step in the 
emergence of a stroke, as well as being of relevance in dementias, 
including Alzheimer’s disease (102).
THe iNFLAMMATORY BACKGROUND  
iN MOOD DiSORDeRS AND CTS
Accumulating evidence has shown that there is a strong correla-
tion between mood disorders and elevated levels of CSF cytokines, 
such as TNF-α and IL-1β, as well as increased PGE2 levels (103). 
Thus, it has been suggested that NKA activity and its modulation 
may also have a pertinent role in the etiology of mental disorders, 
especially bipolar disorder, which is associated with NKA activity 
abnormalities in erythrocytes (104) and high peripheral levels of 
pro-inflammatory cytokines (105).
In samples of bipolar disorders patients, ouabain binding to 
cortex synaptosomal preparations is lower when compared to 
depressed and schizophrenic groups and, at the same time, the 
levels of ouabain were higher in the parietal cortex from these 
patients in comparison with the other groups studied (106). 
However, this difference was not a consequence of changes in the 
expression of the α-NKA isoforms. In the same study, LPS was 
used as a rodent model for depression, leading to an increase in 
the level of ouabain-like compounds in the adrenal gland (106).
However, when animals were treated with anti-ouabain anti-
body or a low dose of ouabain, the depressive behaviors caused by 
LPS was reverted. Although intriguing, the results are complex, 
given that some similar effects were found from the antibody and 
ouabain treatments. First, endogenous ouabain-like compounds 
respond differently from exogenous ouabain; second, different 
CTS can have different physiological outcomes (107) or the use 
of the antibody could have a positive feedback on levels of endog-
enous ouabain-like compounds produced in the brain, leading to 
a similar effect to that of exogenous ouabain (106).
Ouabain, at a high concentration (1  mM), is also used as a 
model of mania, due to NKA inhibition, with this inhibition cor-
relating with the increased cytokine levels, which are also evident 
in bipolar patients (108), as well with the decreased BDNF levels 
in hippocampus and amygdala in this rat model (109). Another 
important feature of ouabain in this model of mania is locomo-
tor hyperactivity, reduced by acute or chronic treatment with 
memantine, lithium (110), or valproate (109). Memantine is a 
well-known NMDA receptor blocker (111), first indicated for the 
treatment of moderate-to-severe Alzheimer’s disease, but that has 
been used off-label to treat various psychiatric disorders, includ-
ing as a mood stabilizer (112). Although the mechanisms by 
which lithium antagonizes ouabain are not clear, it was observed 
in rat hippocampal slices that ouabain (3.3  mM) treatment 
induces cycling electrically evoked epileptiform responses, which 
is delayed by pretreatment with lithium (113).
Another aspect of hyperlocomotion, including the rat ouabain 
model of mania, is increased levels of ROS and protein carbonyl 
levels, as well as the inhibition of catalase and glutathione peroxi-
dase (114). The involvement of oxidative stress in mania was also 
shown following the intracerebroventricular (ICV) injection of 
ouabain (1–10 mM), which increased thiobarbituric acid-reactive 
substances (TBARS) levels and superoxide in the rat amygdala, 
cortex, and striatum (115).
In addition, at high concentration, ouabain ICV injection 
(10  mM) modulates NKA by increasing the expression of α2-
NKA in glial cells of the basal ganglia and α3-NKA in neuron of 
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the frontal cortex, which may be related to hyperactivity behavior. 
When compared to human postmortem studies, a decrease of α2-
NKA expression in temporal cortex of bipolar disorder patients 
was observed, suggesting that the specific NKA isoform expression 
levels may be important to the pathophysiology of mania (116).
Another interesting finding is that endogenous production 
of CTS in bipolar disorder patients also seems to be impaired. 
Bipolar disorder patients have less digoxin-like immunoreactive 
factor in comparison to controls, with this low level not being 
season dependent, as in the case of controls, where winter levels 
are lower than during the rest of the year (117). The ouabain-like 
immunoreactive factor (OLF) is also lower in bipolar disorder 
patients. During physical exercise, OLF is increased in non-
psychiatric patients, but in bipolar disorder patients OLF levels 
tend to be lower, even during exercise. As such, the regulation of 
OLF seems impaired in bipolar disorder patients (118).
A meta-analysis of 30 studies with a total of 2,599 participants 
showed evidence for a significant increase in pro-inflammatory 
and regulatory cytokines in bipolar disorder patients (119). 
However, despite ICV injection of ouabain 10  mM in rats 
mimicking some aspects of bipolar disorder, ouabain injection 
does not increase the inflammatory molecules that are present in 
bipolar disorder patients, with ICV injection of high-dose OUA 
decreasing striatal IL-6 levels (108).
CONCLUSiON AND FUTURe 
PeRSPeCTive
It is clear that NKA is modulated by and modulates inflam-
matory process through its different inflammatory molecules, 
with this occurring in many different ways according to cell 
type, tissue, age, and the dose of its specific CTS ligands, sug-
gesting a complex role for CTS in inflammatory processes. In 
the CNS, inflammation has been suggested as an important 
mediator in major neurodegenerative diseases. As such, the 
role of CTS and NKA in inflammatory process provides a 
significant challenge for future research, including as to the 
role of endogenous CTS and in the modulation of NKA levels 
and activity, which is fundamental for the optimal functioning 
of the synaptic activity of the nervous system. By virtue of its 
involvement in such fundamental processes, the investigation 
of CTS is likely to drive the development of novel therapeutic 
interventions.
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